Your First 90 Days on the Medicare GLP-1 Bridge: What the Labels Actually Say, and Who Adjusts Your Dose

If you are starting Wegovy or Zepbound through the Medicare GLP-1 Bridge, your first 90 days may involve several dose strengths, and the schedules differ. The FDA label for Wegovy starts every adult at 0.25 mg once weekly for weeks 1 through 4, moves to 0.5 mg for weeks 5 through 8, and to 1 mg for weeks 9 through 12. On the standard Wegovy injection schedule, day 90 falls in week 13 at 1.7 mg; interruptions or delayed escalation change that timing. Your prescriber can consider delaying an escalation if a dose is not tolerated. That last sentence is the one that matters most for Bridge patients, because the Bridge is the one GLP-1 access path in the United States that comes with a pharmacy counter and no care team attached.

Why a Bridge first-timer is a different reader

Almost every "first month on a GLP-1" guide on the internet, including ours, was written for someone who signed up with a telehealth programme. That reader has a prescriber in an app, a message thread, and someone whose job it is to notice when week 5 goes badly. A Bridge patient has a prior authorization, a drugstore, and a prescriber they may see twice a year.

That gap is not hypothetical, and the people filling the prescriptions have said so out loud. Walgreens chief pharmacy officer Rick Gates told NPR's Sydney Lupkin on August 26, 2026 that around half of the patients Walgreens has served as part of the Bridge programme had never taken GLP-1s before. He framed the risk plainly: "it's important to make sure patients don't stop therapy because of the initial side effects, such as nausea and diarrhea. Those are the things that pharmacists can really help with." Treat that as a company characterisation given to a reporter rather than a published distribution. Walgreens released no denominator, and neither did CVS.

The volumes behind it are large. CVS told NPR it had filled more than 100,000 Bridge prescriptions as of mid-August, and Walgreens around 100,000. CMS did not give NPR its own figures. If Gates's characterisation holds across the programme, a substantial share of the people now three to eight weeks into a GLP-1 are doing it without the support structure the rest of the market is built around.

The first 90 days, by the label

Wegovy and Zepbound use gradual dose escalation, but their maintenance schedules differ. The Zepbound label includes 5 mg as a maintenance dose for weight reduction, reached after the first four weeks on its labeled schedule. The prescriber selects the maintenance dose based on response and tolerability. The Wegovy injection label uses this adult escalation schedule:

Three things in that table are routinely misread. The 0.25 mg, 0.5 mg and 1 mg doses are initiation and escalation doses; the label does not approve them as maintenance doses. Early results should be discussed with your prescriber in the context of your dose, duration and tolerability. And the schedule is a default, not a deadline: the label says that if you do not tolerate a dose during escalation, your prescriber may consider delaying escalation for 4 weeks.

Zepbound (tirzepatide) runs its own escalation on the same principle. One label change is worth knowing about if you are starting now: the current Zepbound label records that a Severe Gastrointestinal Adverse Reactions warning was added in February 2026, and that the Suicidal Behavior and Ideation section was removed in the same month. A January 2026 change added a warning never to share a KwikPen between patients, which matters in households where two people are on injectable medication.

What to do about a missed dose, before you improvise

Missed doses are common in the first 90 days, and the Wegovy label answers this directly rather than leaving it to a phone call you may not get returned:

• •One dose missed and the next scheduled dose is more than 2 days (48 hours) away: administer as soon as possible.
• •One dose missed and the next scheduled dose is less than 2 days (48 hours) away: do not administer that dose. Resume on your regular day.
• •After two or more consecutive missed injections, contact your prescriber about restarting at a lower dose. Follow the current Wegovy label and your prescribed restart plan.

The restart dose is a prescribing decision. After a prior authorization lapse, supply gap or other interruption, do not assume you should restart at either your previous dose or your original starting dose without checking your plan.

The cautions that are specific to this cohort

The Bridge uses narrower clinical criteria than general weight-management labels. CMS lists BMI 35 or higher; BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a-or-higher chronic kidney disease; or BMI 27 or higher with specified prediabetes or cardiovascular history. These criteria are assessed at treatment initiation. Type 2 diabetes, moderate-to-severe obstructive sleep apnea and noncirrhotic MASH with moderate-to-advanced fibrosis exclude Bridge access. Eligible plan enrollment and prior GLP-1 use also matter. CMS's full criteria and exclusions.

• •Kidney disease and dehydration. A meaningful share of this cohort qualified through chronic kidney disease stage 3a or above. Nausea, vomiting and diarrhoea are the expected early effects, and the fluid loss they cause is not a cosmetic problem when kidney function is already reduced. This is a call-your-prescriber symptom in this group, not a wait-it-out one.
• •Cardiac history. Qualifying through a previous heart attack, a previous stroke, symptomatic peripheral artery disease or heart failure means the reason you are on the drug is cardiovascular. Discuss any plan to pause or stop with the prescriber who authorised it rather than stopping at the counter.
• •Thyroid history is a hard stop. Both labels carry a boxed warning for thyroid C-cell tumours seen in rodents. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. If that history exists in your family and nobody asked, say so before the first injection.
• •Blood sugar, if you take anything else for it. The Wegovy label directs that in patients with type 2 diabetes, blood glucose is monitored before and during treatment. Bridge eligibility excludes type 2 diabetes, but pre-diabetes is a qualifying route, so anyone taking another glucose-lowering medicine should raise it explicitly.

None of this is a reason not to start. It is a reason to have one conversation before week 5 rather than after it.

Your pharmacist is the care team you were not given

Gates's point about pharmacists leaning in is the most actionable thing in the NPR piece, because a pharmacist is free, is open on a Saturday, and has your full medication list in front of them. Four questions are worth asking at the counter on the day you pick up your first pen:

• •Walk me through the injection once, here. Both labels instruct that patients are trained on proper injection technique before initiation, and inspection of the solution before each injection is a labelled step.
• •Does this interact with anything else on my list? This is the question a telehealth intake form asks and a prior authorization does not.
• •What should make me call someone rather than wait? Get the threshold in concrete terms before you need it.
• •If week 5 goes badly, who changes the schedule? The answer is your prescriber, and the answer you want in advance is how to reach them.

For a week-by-week view of the ordinary experience, our first month on a GLP-1 guide covers what tends to happen and when, and the side effects management guide covers the rates and the practical countermeasures. The dosing timeline tool maps the escalation schedule against a start date.

What the $50 does not cover, and what happens in 2028

The Bridge's $50 monthly copayment does not count toward the Part D deductible or out-of-pocket limit. Extra Help cannot lower it, and the Medicare Prescription Payment Plan cannot spread it across months. Keep this separate from your ordinary drug-plan spending when planning your budget. Medicare's current cost rules.

The second is the end date. The Bridge runs from July 2026 through December 2027. Someone starting today and doing well on maintenance will be roughly 16 months into treatment when it stops. Here is what that cliff looks like measured against our own database rather than against a press release. As of September 2, 2026 we track 53 GLP-1 programmes. Not one of them lists a monthly price at or below the Bridge's $50 copay. The cheapest is $69 a month. Nine of the 53 accept insurance at all; 44 do not.

The honest read on that table is that the Bridge is cheaper than anything the cash market currently offers, and that its ending is a real financial event to plan for rather than a marketing hook. KFF put nearly four million Part D enrollees inside the clinical criteria in 2023, so the number of people who will hit that date at once is large. If you want the enrolment mechanics themselves, prior authorization included, they are in our Medicare GLP-1 Bridge enrollment guide, and the wider coverage picture is in our Medicare Part D GLP-1 coverage guide.

Frequently asked questions

How much weight should I expect to lose in the first 90 days? The label does not predict an individual's 90-day weight change. Standard Wegovy injection escalation reaches 1.7 mg in week 13; Zepbound can reach its 5 mg maintenance dose earlier. Your prescriber should assess your response.

Can I stay on a lower dose for longer? That is a prescriber decision, and it is inside the labelled schedule: the label says to consider delaying escalation by 4 weeks where a dose is not tolerated.

Is compounded semaglutide a cheaper way to do this? Compounded GLP-1 medications are not FDA-approved, and the labels quoted throughout this article do not apply to them. That is a separate decision from the one this page is about.

Does the Bridge cover Ozempic or Mounjaro? No. The programme covers Wegovy, Zepbound and Foundayo, the products approved for chronic weight management.

Sources